Breakthrough research revolutionizing pulmonary hypertension treatment

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for pulmonary hypertension (PH), a condition that places patients at risk for right heart failure and death. Co-authored by Dr. James Jenkins, a cardiologist at Ochsner Health, the study analyzed data from multiple clinical trials to assess the therapeutic and clinical impact of PADN in PH patients. 

PADN has emerged as a promising treatment, showing significant improvements in several key hemodynamic parameters and clinical outcomes. The meta-analysis, which reviewed 14 studies involving 372 patients, revealed that PADN could reduce metrics such as mean right atrial pressure (mRAP), mean pulmonary artery pressure (mPAP), and pulmonary vascular resistance (PVR). Simultaneously, it improved cardiac output (CO) and performance on the six-minute walk test (6MWT), highlighting its potential to enhance overall patient health. 

Despite these encouraging results, the authors emphasize the importance of conducting larger-scale clinical trials to confirm PADN’s efficacy, establish its safety profile, and refine treatment protocols. Future research should also investigate the procedure’s long-term effects on patient outcomes and quality of life. 

"Pulmonary artery denervation has become a promising therapeutic intervention in the management of pulmonary hypertension,” commented Dr. Jenkins. “While our findings suggest a substantial role for PADN in treatment protocols, continuous research is crucial to fully understand its broader implications and long-term benefits.” 

As cardiovascular disease remains a leading cause of death globally, advancements like this represent critical progress in addressing life-threatening conditions. This study not only underscores the value of innovation in cardiology but also highlights the ongoing need for rigorous research to develop more effective and life-changing treatments for patients with complex conditions like pulmonary hypertension. 

### 

About Ochsner Health  

Ochsner Health is the leading nonprofit healthcare provider in the Gulf South, delivering expert care at its 46 hospitals and more than 370 health and urgent care centers. For 13 consecutive years, U.S. News & World Report has recognized Ochsner as the No. 1 hospital in Louisiana. Additionally, Ochsner Children’s has been recognized as the No. 1 hospital for kids in Louisiana for four consecutive years. Ochsner inspires healthier lives and stronger communities through a combination of standard-setting expertise, quality and digital connectivity not found anywhere else in the region. In 2024, Ochsner Health cared for more than 1.6 million people from every state in the nation and 63 countries. Ochsner’s workforce includes more than 40,000 dedicated team members and over 4,900 employed and affiliated physicians. To learn more about how Ochsner empowers people to get well and stay well, visit https://www.ochsner.org/.